Last reviewed · How we verify

Tranexamic Acid plus standard of care

Pfizer · FDA-approved active Small molecule Quality 2/100

Tranexamic Acid plus standard of care is a Antifibrinolytic agent Small molecule drug developed by Pfizer. It is currently FDA-approved for Reduction of blood loss in surgical procedures, Treatment of bleeding in trauma patients, Prevention of excessive bleeding in hemophilia patients undergoing surgery.

Tranexamic acid inhibits fibrinolysis by blocking plasminogen activation, thereby reducing bleeding and promoting clot stability.

Tranexamic acid inhibits fibrinolysis by blocking plasminogen activation, thereby reducing bleeding and promoting clot stability. Used for Reduction of blood loss in surgical procedures, Treatment of bleeding in trauma patients, Prevention of excessive bleeding in hemophilia patients undergoing surgery.

At a glance

Generic nameTranexamic Acid plus standard of care
SponsorPfizer
Drug classAntifibrinolytic agent
TargetPlasminogen / Plasmin
ModalitySmall molecule
Therapeutic areaHematology / Surgery / Trauma
PhaseFDA-approved

Mechanism of action

Tranexamic acid is an antifibrinolytic agent that competitively inhibits the binding of plasminogen and plasmin to fibrin, preventing the breakdown of blood clots. By reducing fibrinolysis, it helps maintain hemostasis and reduce blood loss in surgical and trauma settings. When combined with standard of care, it enhances the overall hemostatic effect in clinical scenarios where excessive bleeding is a concern.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Tranexamic Acid plus standard of care

What is Tranexamic Acid plus standard of care?

Tranexamic Acid plus standard of care is a Antifibrinolytic agent drug developed by Pfizer, indicated for Reduction of blood loss in surgical procedures, Treatment of bleeding in trauma patients, Prevention of excessive bleeding in hemophilia patients undergoing surgery.

How does Tranexamic Acid plus standard of care work?

Tranexamic acid inhibits fibrinolysis by blocking plasminogen activation, thereby reducing bleeding and promoting clot stability.

What is Tranexamic Acid plus standard of care used for?

Tranexamic Acid plus standard of care is indicated for Reduction of blood loss in surgical procedures, Treatment of bleeding in trauma patients, Prevention of excessive bleeding in hemophilia patients undergoing surgery.

Who makes Tranexamic Acid plus standard of care?

Tranexamic Acid plus standard of care is developed and marketed by Pfizer (see full Pfizer pipeline at /company/pfizer).

What drug class is Tranexamic Acid plus standard of care in?

Tranexamic Acid plus standard of care belongs to the Antifibrinolytic agent class. See all Antifibrinolytic agent drugs at /class/antifibrinolytic-agent.

What development phase is Tranexamic Acid plus standard of care in?

Tranexamic Acid plus standard of care is FDA-approved (marketed).

What are the side effects of Tranexamic Acid plus standard of care?

Common side effects of Tranexamic Acid plus standard of care include Thromboembolic events (deep vein thrombosis, pulmonary embolism), Nausea and vomiting, Diarrhea, Headache, Visual disturbances.

What does Tranexamic Acid plus standard of care target?

Tranexamic Acid plus standard of care targets Plasminogen / Plasmin and is a Antifibrinolytic agent.

Related